https://novapharmanews.com/us/news/fda-in-flux-may-2026-drug-approvals-update 2026-05-22T21:13:00.626Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z FDA in Flux: May 2026 Drug Approvals Update https://novapharmanews.com/uploads/articles/fda-in-flux-may-2026-drug-approvals-update.webp FDA in Flux: May 2026 Drug Approvals Update https://novapharmanews.com/eu/news/serb-pharma-acquires-idefirix-rights 2026-05-22T20:13:09.024Z NovaPharmaNews en-GB 2026-05-22T08:17:18.618Z SERB Pharma Acquires Idefirix Rights from Hansa Idefirix https://novapharmanews.com/uploads/articles/serb-pharma-acquires-idefirix-rights.webp SERB Pharma Acquires Idefirix Rights from Hansa https://novapharmanews.com/eu/news/chmp-meeting-highlights-drug-approvals-april-2026 2026-05-22T21:26:58.326Z NovaPharmaNews en-GB 2026-05-22T08:17:18.618Z CHMP Meeting Highlights: Drug Approvals from April 2026 https://novapharmanews.com/uploads/articles/chmp-meeting-highlights-drug-approvals-april-2026.webp CHMP Meeting Highlights: Drug Approvals from April 2026 https://novapharmanews.com/apac/news/ildong-pharmaceutical-stock-earnings-pipeline-insights 2026-05-22T21:13:36.613Z NovaPharmaNews en-AU 2026-05-22T08:17:18.618Z Ildong Pharmaceutical Stock: Earnings and Pipeline Insights https://novapharmanews.com/uploads/articles/ildong-pharmaceutical-stock-earnings-pipeline-insights.webp Ildong Pharmaceutical Stock: Earnings and Pipeline Insights https://novapharmanews.com/us/news/fda-fast-track-oncology-drugs-april-2026 2026-05-22T21:13:10.030Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z FDA Fast Track Designation for Oncology Drugs: April 2026 Insights oncology https://novapharmanews.com/uploads/articles/fda-fast-track-oncology-drugs-april-2026.webp FDA Fast Track Designation for Oncology Drugs: April 2026 Insights https://novapharmanews.com/us/news/fda-guidance-animal-testing-alternatives-concerns 2026-05-22T21:13:35.096Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z FDA's Guidance on Animal Testing Alternatives: Industry Concerns https://novapharmanews.com/uploads/articles/fda-guidance-animal-testing-alternatives-concerns.webp FDA's Guidance on Animal Testing Alternatives: Industry Concerns https://novapharmanews.com/us/news/liminatus-acquires-innocsai-320m-car-t-bet 2026-05-22T21:13:39.768Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z Liminatus Acquires InnocsAI: A $320M CAR-T Bet https://novapharmanews.com/uploads/articles/liminatus-acquires-innocsai-320m-car-t-bet.webp Liminatus Acquires InnocsAI: A $320M CAR-T Bet https://novapharmanews.com/us/news/aptar-pharma-fda-research-contract-progress 2026-05-22T21:31:29.305Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z Aptar Pharma Advances FDA-Funded Research Contract for Drug Approvals https://novapharmanews.com/uploads/articles/aptar-pharma-fda-research-contract-progress.webp Aptar Pharma Advances FDA-Funded Research Contract for Drug Approvals https://novapharmanews.com/eu/news/teva-olan-ema-acceptance 2026-05-22T20:29:48.132Z NovaPharmaNews en-GB 2026-05-22T08:17:18.618Z Teva's Olan Application Accepted by EMA: What It Means for Pharma Olan https://novapharmanews.com/uploads/articles/teva-olan-ema-acceptance.webp Teva's Olan Application Accepted by EMA: What It Means for Pharma https://novapharmanews.com/us/news/best-cancer-stocks-2026-investment 2026-05-22T21:27:44.799Z NovaPharmaNews en-US 2026-05-22T08:17:18.618Z Best Cancer Stocks for 2026: Investment Insights oncology, cancer https://novapharmanews.com/uploads/articles/best-cancer-stocks-2026-investment.webp Best Cancer Stocks for 2026: Investment Insights https://novapharmanews.com/apac/news/kelun-merck-lung-cancer-combo-china-trial 2026-05-22T20:30:37.024Z NovaPharmaNews en-AU 2026-05-22T08:17:18.618Z Kelun and Merck's Lung Cancer Combo Shows Promise in China oncology, lung cancer https://novapharmanews.com/uploads/articles/kelun-merck-lung-cancer-combo-china-trial.webp Kelun and Merck's Lung Cancer Combo Shows Promise in China https://novapharmanews.com/eu/news/mhra-consultation-rare-disease-therapy 2026-05-22T21:12:42.905Z NovaPharmaNews en-GB 2026-05-22T08:17:18.618Z MHRA Consultation on Rare Disease Therapy Draft Guidance rare disease https://novapharmanews.com/uploads/articles/mhra-consultation-rare-disease-therapy.webp MHRA Consultation on Rare Disease Therapy Draft Guidance https://novapharmanews.com/us/news/new-fda-guidance-ends-nicotine-pouches 2026-05-22T20:41:15.309Z NovaPharmaNews en-US 2026-05-21T08:07:20.460Z New FDA Guidance on ENDS and Nicotine Pouch Products https://novapharmanews.com/uploads/articles/new-fda-guidance-ends-nicotine-pouches.webp New FDA Guidance on ENDS and Nicotine Pouch Products https://novapharmanews.com/us/news/biomarin-swot-analysis-rare-disease-biotech 2026-05-22T08:14:22.980Z NovaPharmaNews en-US 2026-05-21T08:07:20.460Z BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech rare disease https://novapharmanews.com/uploads/articles/biomarin-swot-analysis-rare-disease-biotech.webp BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech https://novapharmanews.com/eu/news/first-glp-1-gene-therapy-clinical-trial-europe 2026-05-22T21:13:29.120Z NovaPharmaNews en-GB 2026-05-21T08:07:20.460Z First GLP-1 Gene Therapy Clinical Trial Approved in Europe GLP-1, gene therapy https://novapharmanews.com/uploads/articles/first-glp-1-gene-therapy-clinical-trial-europe.webp First GLP-1 Gene Therapy Clinical Trial Approved in Europe https://novapharmanews.com/us/news/takeda-novartis-layoffs-pharma-impact 2026-05-22T21:26:57.592Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z Takeda and Novartis Layoffs: Implications for Pharma Industry https://novapharmanews.com/uploads/articles/takeda-novartis-layoffs-pharma-impact.webp Takeda and Novartis Layoffs: Implications for Pharma Industry https://novapharmanews.com/us/news/fda-alert-pulmonology-drug-approvals 2026-05-22T21:17:48.769Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z FDA Alert: Key Updates on Pulmonology Drug Approvals https://novapharmanews.com/uploads/articles/fda-alert-pulmonology-drug-approvals.webp FDA Alert: Key Updates on Pulmonology Drug Approvals https://novapharmanews.com/us/news/migraine-drugmaker-reverse-merger-market-analysis 2026-05-22T21:26:56.822Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z Migraine Drugmaker's Reverse Merger: Market Insights migraine https://novapharmanews.com/uploads/articles/migraine-drugmaker-reverse-merger-market-analysis.webp Migraine Drugmaker's Reverse Merger: Market Insights https://novapharmanews.com/us/news/2026-pharma-ma-breakout-year 2026-05-22T21:17:58.443Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z Will 2026 Be Pharma’s M&A Breakout Year? Market Analysis https://novapharmanews.com/uploads/articles/2026-pharma-ma-breakout-year.webp Will 2026 Be Pharma’s M&A Breakout Year? Market Analysis https://novapharmanews.com/us/news/fda-expands-market-access-ends-products 2026-05-22T20:25:48.772Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z FDA Expands Market Access for ENDS Products: What You Need to Know https://novapharmanews.com/uploads/articles/fda-expands-market-access-ends-products.webp FDA Expands Market Access for ENDS Products: What You Need to Know https://novapharmanews.com/us/news/fda-lifting-restrictions-compounded-peptides 2026-05-22T07:20:53.770Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z FDA to Consider Lifting Restrictions on Compounded Peptides https://novapharmanews.com/uploads/articles/fda-lifting-restrictions-compounded-peptides.webp FDA to Consider Lifting Restrictions on Compounded Peptides https://novapharmanews.com/us/news/regeneron-pharma-stock-institutional-buying-insights 2026-05-22T21:13:30.059Z NovaPharmaNews en-US 2026-05-21T08:06:59.876Z Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights https://novapharmanews.com/uploads/articles/regeneron-pharma-stock-institutional-buying-insights.webp Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights https://novapharmanews.com/apac/news/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit 2026-05-22T20:14:05.726Z NovaPharmaNews en-AU 2026-05-21T08:06:52.523Z Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance https://novapharmanews.com/uploads/articles/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit.webp Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance https://novapharmanews.com/apac/news/zte-partners-china-national-clinical-research-center 2026-05-22T05:17:01.804Z NovaPharmaNews en-AU 2026-05-21T08:06:52.523Z ZTE Partners with China's National Clinical Research Center for Clinical Trials https://novapharmanews.com/uploads/articles/zte-partners-china-national-clinical-research-center.webp ZTE Partners with China's National Clinical Research Center for Clinical Trials https://novapharmanews.com/eu/news/florian-lordick-esmo-president-2026-elections-open 2026-05-22T20:13:12.800Z NovaPharmaNews en-GB 2026-05-21T08:06:52.523Z Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology oncology https://novapharmanews.com/uploads/articles/florian-lordick-esmo-president-2026-elections-open.webp Florian Lordick Elected 2026 ESMO President: Implications for Global Oncology https://novapharmanews.com/apac/news/kissei-pharmaceutical-halts-tavneos-use-amid-deaths 2026-05-22T20:20:43.404Z NovaPharmaNews en-AU 2026-05-21T08:06:52.523Z Kissei Pharmaceutical Halts Tavneos Use Amid Deaths Tavneos https://novapharmanews.com/uploads/articles/kissei-pharmaceutical-halts-tavneos-use-amid-deaths.webp Kissei Pharmaceutical Halts Tavneos Use Amid Deaths https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-18-may-2026 2026-05-22T21:15:15.295Z NovaPharmaNews en-AU 2026-05-21T08:06:52.523Z Regulatory Round-Up: Drug Approvals on 18 May 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-18-may-2026.webp Regulatory Round-Up: Drug Approvals on 18 May 2026 https://novapharmanews.com/eu/news/february-batch-novel-medicines-ema-chmp-approval 2026-05-22T21:17:54.057Z NovaPharmaNews en-GB 2026-05-21T08:06:52.523Z February Batch of Novel Medicines Recommended for Approval by EMA/CHMP https://novapharmanews.com/uploads/articles/february-batch-novel-medicines-ema-chmp-approval.webp February Batch of Novel Medicines Recommended for Approval by EMA/CHMP https://novapharmanews.com/eu/news/fda-approves-aldosterone-synthase-inhibitor-hypertension 2026-05-22T20:16:02.736Z NovaPharmaNews en-GB 2026-05-21T08:06:52.523Z FDA Approves First-in-Class Aldosterone Synthase Inhibitor for Uncontrolled Hypertension aldosterone synthase inhibitor, uncontrolled hypertension https://novapharmanews.com/uploads/articles/fda-approves-aldosterone-synthase-inhibitor-hypertension.webp FDA Approves First-in-Class Aldosterone Synthase Inhibitor for Uncontrolled Hypertension https://novapharmanews.com/apac/news/novartis-pluvicto-stronger-psa-responses-prostate-cancer 2026-05-22T20:37:35.735Z NovaPharmaNews en-AU 2026-05-21T08:06:52.523Z Novartis Strengthens Prostate Cancer Treatment with Pluvicto Pluvicto, oncology, prostate cancer https://novapharmanews.com/uploads/articles/novartis-pluvicto-stronger-psa-responses-prostate-cancer.webp Novartis Strengthens Prostate Cancer Treatment with Pluvicto